stonks4u
Sign up free
KYTX logo

KYTX Kyverna Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$8.17
+0.09 (+1.11%)

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also develop…

Market Cap: $496.70Mkyvernatx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 11Aug 13

Quote

Day Range
$7.82 – $8.29
52-Week Range
$3.27 – $13.67
Volume
$571.1K
Market Cap
$496.70M
50-Day Avg
$8.04
200-Day Avg
$8.31
Prev Close
$8.08
Open
$7.96

Valuation & Ratios

P/E Ratio
-2.58
EPS
$-3.64
P/B Ratio
1.79
P/S Ratio
0.00
Debt/Equity
0.12
Current Ratio
7.75
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-69.4%
Return on Assets
-54.9%
FCF Yield
-36.9%
EV/EBITDA
-2.02

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-161.31M$-3.64
2024$0.00$-127.48M$-3.33
2023$0.00$-60.37M$-0.00
2022$7.03M$-28.89M$-1.12
2021$5.66M$-26.35M$-1.02

Social Signal Score

51
5d
51
2 mentions
—
30d
51
2 mentions
—
60d
51
2 mentions
—
90d
51
2 mentions
—
news: 2

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.73 per share

6of 7 quarters beat consensus

Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.63 vs $-0.68beat
  • Tue, May 12$-0.66 vs $-0.75beat
  • Thu, Mar 26$-0.80 vs $-0.84beat
  • Wed, Nov 12$-0.85 vs $-0.97beat
  • Tue, Aug 12$-0.97 vs $-1.00beat
  • Tue, May 13$-1.03 vs $-1.21beat

Estimates and results for KYTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

KYTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·2d ago·Neutral

    Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026 and potentia

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology

    View source ↗